Personalization of Ductal Carcinoma In-Situ Management: Large Databases and an Emerging Role for Global Data Sharing
Abstract
NA
Full text article
References
Mannu GS, Wang Z, Broggio J, Charman J, Cheung S, Kearins O, et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ. 2020;369.
Giannakeas V, Sopik V, Narod SA. Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA Network Open. 2020;3(9):e2017124-e.
Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor–positive ductal carcinoma in situ: a study based on NSABP protocol B-24. Journal of Clinical Oncology. 2012;30(12):1268.
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. The lancet oncology. 2011;12(1):21-9.
Group EBCTC. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute Monographs. 2010;2010(41):162-77.
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis ofductal carcinoma in situ. JAMA oncology. 2015;1(7):888-96.
Esserman L, Yau C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA oncology. 2015;1(7):881-3.
Kim SH, Ferrante J, Won BR, Hameed M. Barriers to adequate follow-up during adjuvant therapy may be important factors in the worse outcome for Black women after breast cancer treatment. World Journal of Surgical Oncology. 2008;6(1):26.
Liu Y, Colditz GA, Gehlert S, Goodman M. Racial disparities in risk of second breast tumors after ductal carcinoma in situ. Breast cancer research and treatment. 2014;148(1):163-73.
Madubata CC, Liu Y, Goodman MS, Yun S, Yu J, Lian M, et al. Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race. Breast cancer Research and Treatment. 2016;160(3):563-72.
Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an invasive breast Cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiology and Prevention Biomarkers. 2019;28(5):835-45.
Borgquist S, Zhou W, Jirström K, Amini R-M, Sollie T, Sørlie T, et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC cancer. 2015;15(1):1-10.
Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. Journal of Cancer. 2011;2:232-261.
Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol J-P, et al. Biological markers predictive of invasive recurrence in DCIS. Clinical Medicine Oncology. 2008;2:117955490800200202.
O'Keefe TJ, Blair SL, Hosseini A, Harismendy O, Wallace AM. HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence. Cancer Prevention Research. 2020;13(9):761-72.
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Cancer outcomes in DCIS patients without locoregional treatment. JNCI: Journal of the National Cancer Institute. 2019;111(9):952-60.
Sopik V, Sun P, Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast cancer research and treatment. 2018;167(3):787-95.
Baker JL, Mailey B, Tokin CA, Blair SL, Wallace AM. Postmastectomy reconstruction is associated with improved survival in patients with invasive breast cancer: a single-institution study. The American Surgeon. 2013;79(10):977-81.
Bezuhly M, Temple C, Sigurdson LJ, Davis RB, Flowerdew G, Cook Jr EF. Immediate postmastectomy reconstruction is associated with improved breast cancer?specific survival: evidence and new challenges from the Surveillance, Epidemiology, and End Results database. Cancer. 2009;115(20):4648-54.
Semple JL, Metcalfe K, Shoukat F, Sun P, Narod S. Survival differences in women with and without autologous breast reconstruction after mastectomy for breast cancer. Plastic and Reconstructive Surgery Global Open. 2017;5(4).
Boice Jr JD, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. New England Journal of Medicine. 1992;326(12):781-5.
Mohanty S, Bilimoria KY. Comparing national cancer registries: the National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program. Journal of Surgical Oncology. 2014;109(7):629.
Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, et al. Using the National Cancer Database for outcomes research: a review. JAMA oncology. 2017;3(12):1722-8.
James BY, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology. 2009;23(3):288.
O’Keefe TJ, Wallace AM. Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis. Breast Cancer Research and Treatment. 2020;182(3):761-2.
Authors
Copyright (c) 2021 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.